Arbutus reports first quarter 2020 financial results

Arbutus reports first quarter 2020 financial results, provides pipeline update and announces new research initiative to identify novel antiviral therapies for the treatment of coronavirus infections.q1 loss per share $0.25.q1 earnings per share estimate $-0.31 -- refinitiv ibes data.on track to have additional results from week 12 portion of 60 mg single-dose cohort in q2.establishment of covid-19 effort does not impact arbutus' current cash burn guidance for 2020 of $54 to $58 million.
ABUS Ratings Summary
ABUS Quant Ranking